GLP-1 drugs for addiction are attracting attention for a reason: clinical trials suggest semaglutide can reduce some measures of drinking and alcohol craving. But Ozempic and Wegovy have not been shown to cure alcohol or opioid addiction, and neither has a US approval for treating these disorders.
The distinction matters if you or someone you love is looking for help. Alcohol research now includes randomized trials published in 2026. Opioid research remains less conclusive. Neither justifies replacing established addiction care with a weight-loss medication.
Why a diabetes medication might affect cravings
Ozempic and Wegovy contain semaglutide, which activates receptors for glucagon-like peptide-1, or GLP-1. This signaling system helps regulate blood sugar and appetite. Researchers are also investigating its influence on brain pathways involved in reward and motivation.
That provides a biological reason to study GLP-1 drugs for addiction. If a medication changes how strongly someone responds to a rewarding substance, it might make cravings easier to manage. However, a plausible mechanism does not establish which patients benefit or whether improvement lasts.
The brands also have different approved uses and prescribing instructions. Sharing an ingredient does not make their products interchangeable or establish an addiction-treatment dose.
What alcohol studies actually show
The strongest evidence for GLP-1 drugs for addiction currently comes from alcohol research, although the studies differ in participants, treatment duration, and outcomes.
The small 2025 trial
A randomized trial published online in JAMA Psychiatry in February 2025 enrolled 48 adults with alcohol use disorder who were not seeking treatment. Over nine weeks, low-dose semaglutide reduced alcohol craving and drinks consumed on drinking days compared with placebo.
It did not significantly reduce the number of drinking days or average drinks per calendar day. Those mixed findings matter: the study supported further investigation, not a claim that participants stopped drinking or recovered permanently.
Longer treatment in people with obesity
A 2026 trial in The Lancet studied 108 treatment-seeking adults with moderate to severe alcohol use disorder and obesity. Participants received semaglutide or placebo for 26 weeks, alongside cognitive behavioral therapy.
The estimated treatment difference in the reduction of heavy-drinking days was 13.7 percentage points in favor of semaglutide. That is a difference between study groups, not a 13.7% cure rate.
This strengthens the case for studying GLP-1 drugs for addiction, particularly when alcohol problems and obesity coexist. But the trial involved a specific population and included therapy. It does not show that medication alone produces the same results in everyone.
Oral semaglutide adds another signal
A separate randomized trial published in the American Journal of Psychiatry in 2026 reported reductions in alcohol consumption, everyday alcohol craving, and alcohol-related problems among treatment-seeking participants receiving oral semaglutide.
Together, these studies move research on GLP-1 drugs for addiction beyond personal testimonials. They still leave questions about long-term outcomes, treatment selection, and what happens after medication stops.
What about opioid addiction?
Research on GLP-1 drugs and opioid addiction needs its own assessment. Alcohol findings cannot establish that semaglutide treats opioid use disorder.
A 2024 JAMA Network Open study examined health records from people with both type 2 diabetes and opioid use disorder. Semaglutide prescriptions were associated with lower opioid overdose risk than several other diabetes treatments.
Because researchers analyzed existing records rather than randomly assigning treatment, the study cannot prove semaglutide caused that difference. Differences in health, access to care, and other treatments could help explain the association.
A 2026 retrospective study also reported associations between GLP-1 receptor agonist use and lower mortality and overdose risk in people with opioid use disorder. It adds supporting evidence, but not randomized proof.
The next step for GLP-1 drugs for addiction is testing whether these associations translate into reliable treatment benefits. One published trial protocol plans to evaluate semaglutide in 200 people already receiving methadone or buprenorphine who continue to use nonprescribed opioids.
That design asks whether semaglutide can add benefit to established medication. A trial protocol describes planned research; it is not a positive trial result.
Why “cure” is the wrong promise
Studies of GLP-1 drugs for addiction measure different things: cravings, drinking patterns, drug use, or recorded overdoses. Improvement in one outcome does not automatically mean improvement in all of them.
A useful way to read a headline is to ask three questions:
- Who participated? People with obesity and alcohol use disorder may respond differently from other patients.
- What improved? Fewer heavy-drinking days is meaningful, but it is different from sustained abstinence.
- For how long? Improvement during treatment does not establish lasting recovery after stopping it.
Recovery can involve ongoing medication, behavioral care, and support. Needing continued treatment does not mean a person has failed.
The practical question is whether GLP-1 drugs for addiction can safely improve outcomes within that broader care plan.
What treatment is available now?
People seeking help do not need to wait for semaglutide research to mature.
For alcohol use disorder, FDA-approved medications include naltrexone, acamprosate, and disulfiram. They work differently, and a clinician can help determine which option fits a person's health, goals, and other medications. Behavioral treatment and mutual-support groups can also contribute to recovery.
For opioid use disorder, established medications include buprenorphine, methadone, and naltrexone. Do not stop prescribed treatment because a headline suggests Ozempic might reduce cravings.
GLP-1 drugs for addiction are not substitutes for emergency care, either. Naloxone reverses opioid overdose; semaglutide does not. If an opioid overdose is suspected, administer naloxone if available and call 911.
People who drink heavily over a prolonged period should seek medical guidance before abruptly stopping. Alcohol withdrawal can cause seizures and other life-threatening complications. Reduced interest in alcohol does not establish that withdrawal will be safe. NIAAA
Safety questions deserve equal attention
Considering GLP-1 drugs for addiction also means considering their risks. Common semaglutide side effects include nausea, vomiting, diarrhea, constipation, and abdominal pain.
Prescribing information also includes warnings about pancreatitis, gallbladder problems, and kidney injury associated with dehydration. Semaglutide is not recommended for people with severe gastroparesis, a condition that substantially delays stomach emptying. novo-pi.com
The boxed warning concerns thyroid C-cell tumors observed in rodents; whether semaglutide causes these tumors in humans is unknown. People with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not use it.
A clinician should review nutrition, pregnancy plans, other medications, and medical history before prescribing. An existing prescription for obesity or diabetes does not automatically address addiction-related needs.
A practical conversation to have with your clinician
If you want to discuss GLP-1 drugs for addiction, bring a list of medications and an honest description of alcohol or opioid use, cravings, and previous treatment.
Ask:
- Which established treatments fit my situation now?
- Do I separately qualify for semaglutide for an approved condition?
- Would addiction-focused use be off-label, and what uncertainties would that involve?
- Is there a suitable clinical trial?
- How would we track benefits, side effects, and continued substance use?
For GLP-1 drugs for addiction, progress should be judged by measurable health improvements and safety, not by the promise of effortless recovery.
Start with a primary care clinician or addiction specialist. The NIAAA Alcohol Treatment Navigator and FindTreatment.gov can help locate care. Research may expand tomorrow's options, but effective treatment deserves a place in today's plan.
This article provides general health information and is not a substitute for individualized medical care.
